AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27496577 — intervention group
Group type: COMPARATOR
Intervention: BTX‐A injections in the temporal and masseter muscles only (Group B)
Number of subjects: 20
Study 25918808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 56
Study 25918808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25918808 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 56
Study 22746075 — intervention group
Group type: EXPERIMENTAL
Intervention: TNP laparostomy
Number of subjects: 57
Study 22746075 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 57
Study 20405784 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel electrode orientation
Number of subjects: 10
Study 20405784 — intervention group
Group type: COMPARATOR
Intervention: Perpendicular electrode orientation
Number of subjects: 10
Study 20405784 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel and Perpendicular electrode orientations
Number of subjects: 10
Study 18505783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melphalan, prednisone, and thalidomide (MPT)
Number of subjects: 0
Study 18505783 — intervention group
Group type: COMPARATOR
Intervention: Standard melphalan and prednisone (MP)
Number of subjects: 0
Study 18505783 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide or bortezomib as salvage regimens in MP group
Number of subjects: 0
Study 18505783 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide or bortezomib as salvage regimens in MPT group
Number of subjects: 0
Study 16015051 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0
Study 12629058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 5 microg/kg
Number of subjects: 43
Study 12629058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 10 microg/kg
Number of subjects: 43
Study 12629058 — intervention group
Group type: COMPARATOR
Intervention: Lenograstim 2 microg/kg
Number of subjects: 43
Study 10537443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg twice daily)
Number of subjects: 100
Study 10537443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg twice daily) plus Loviride (100 mg 3 times daily)
Number of subjects: 100
Study 10537443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8777105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy group (n = 15) with minimal flow (0.5 litre min‐1) and fuzzy logic feedback control of gas concentrations
Number of subjects: 30
Study 8777105 — intervention group
Group type: COMPARATOR
Intervention: Standard group (n = 15) with low flow anaesthesia (1.2‐1.3 litre min‐1) and manual control of gas concentrations
Number of subjects: 30
Study 2054076 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE-TEX bags containing silver sulphadiazine cream
Number of subjects: 0
Study 2054076 — intervention group
Group type: COMPARATOR
Intervention: Polythene bags
Number of subjects: 0
Study 2054076 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE-TEX bags
Number of subjects: 0
Study 2054076 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE-TEX bags and Polythene bags
Number of subjects: 0
Study 6423263 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy alone
Number of subjects: 247
Study 6423263 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy combined with 5-fluorouracil
Number of subjects: 247
Study 30620151 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (operant conditioning with rewards and punishments)
Number of subjects: 0
Study 30620151 — intervention group
Group type: COMPARATOR
Intervention: Random-control group (non-contingent rewards and punishments)
Number of subjects: 0
Study 30620151 — intervention group
Group type: COMPARATOR
Intervention: Colour-control group (no rewards or punishments)
Number of subjects: 0
Study 29913015 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 116
Study 29913015 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 116
Study 27410169 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed co‐polyester oral splints (Group B)
Number of subjects: 36
Study 27410169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated oral splints with water‐filled elastic pads (Group A)
Number of subjects: 36
Study 27410169 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan‐type hard splints (Group C)
Number of subjects: 36
Study 27410169 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 36
Study 27410169 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 36
Study 25386778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not available)
Number of subjects: 194
Study 25386778 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific control details not available)
Number of subjects: 194
Study 22587540 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientifically determined nutrition strategy (S)
Number of subjects: 18
Study 22587540 — intervention group
Group type: COMPARATOR
Intervention: Self-chosen nutrition strategy (A)
Number of subjects: 18
Study 19860749 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 20 mg (5 mg/ml)
Number of subjects: 60
Study 19860749 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 80 mg (20 mg/ml)
Number of subjects: 60
Study 19860749 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 60
Study 17606957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C level
Number of subjects: 825
Study 17606957 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine concentration
Number of subjects: 825
Study 17606957 — intervention group
Group type: EXPERIMENTAL
Intervention: Iothalamate GFR
Number of subjects: 825
Study 16525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealer device
Number of subjects: 50
Study 16525984 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 50
Study 12384409 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Number of subjects: 101
Study 12384409 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM) transplantation
Number of subjects: 101
Study 12384409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic GVHD treatment
Number of subjects: 101
Study 10439747 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal PGE1 (0.15‐3.6 micrograms/kg) every 6 hours for up to 7 days
Number of subjects: 28
Study 10439747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7872852 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention provided to physicians
Number of subjects: 56
Study 7872852 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians who received the consultation letter after 12 months)
Number of subjects: 56
Study 7872852 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention
Number of subjects: 56
Study 2087863 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (3-4 sessions per day, 5 days a week, intensity up to 1 W/kg body weight)
Number of subjects: 39
Study 2087863 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (specifically for EF less than 30%)
Number of subjects: 39
Study 2087863 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 39
Study 2087863 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (for EF greater than 30%)
Number of subjects: 39
Study 2087863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 32111 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded clip technique
Number of subjects: 599
Study 32111 — intervention group
Group type: COMPARATOR
Intervention: Tubal ring technique
Number of subjects: 599
Study 30722062 — intervention group
Group type: EXPERIMENTAL
Intervention: menthol Tobacco Heating System (mTHS) 2.2
Number of subjects: 160
Study 30722062 — intervention group
Group type: COMPARATOR
Intervention: menthol cigarettes (mCCs)
Number of subjects: 160
Study 30722062 — intervention group
Group type: COMPARATOR
Intervention: smoking abstinence (SA)
Number of subjects: 160
Study 31064236 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Platelet-rich plasma (PRP) applied twice a day for 12 weeks
Number of subjects: 50
Study 31064236 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and betamethasone for the first 7 days, then hyaluronic acid gel for 12 weeks
Number of subjects: 50
Study 26704712 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (200 mg)
Number of subjects: 54
Study 26704712 — intervention group
Group type: COMPARATOR
Intervention: Control (starch, 200 mg)
Number of subjects: 54
Study 25010702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 20
Study 25010702 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial Treatment as Usual (TAU)
Number of subjects: 20
Study 23915854 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based health management platform (HMP)
Number of subjects: 66
Study 23915854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 22000135 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cerebral perfusion (ACP)
Number of subjects: 74
Study 22000135 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 74
Study 19963099 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly (175/75)
Number of subjects: 162
Study 19963099 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice therapy
Number of subjects: 162
Study 17407035 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 203
Study 17407035 — intervention group
Group type: COMPARATOR
Intervention: Group C meningococcal conjugate vaccine
Number of subjects: 203
Study 15523338 — intervention group
Group type: EXPERIMENTAL
Intervention: Axis Dental polishing system
Number of subjects: 63
Study 15523338 — intervention group
Group type: EXPERIMENTAL
Intervention: Brasseler polishing system
Number of subjects: 63
Study 15523338 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelenko polishing system
Number of subjects: 63
Study 15523338 — intervention group
Group type: COMPARATOR
Intervention: Control (autoglazed surface)
Number of subjects: 63
Study 11233898 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive or prophylactic lamivudine treatment (n=10)
Number of subjects: 36
Study 11233898 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage lamivudine treatment after hepatic dysfunction (n=6)
Number of subjects: 36
Study 11233898 — intervention group
Group type: COMPARATOR
Intervention: Non-lamivudine treated group (control group, n=25)
Number of subjects: 36
Study 11233898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine treatment (n=3)
Number of subjects: 36
Study 9780618 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS5MN) 20 mg bid (8.00 am and 3.00 pm) for 1 week (Group 1)
Number of subjects: 10
Study 9780618 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS5MN) 40 mg bid (8.00 am and 8.00 pm) for 1 week (Group 2)
Number of subjects: 10
Study 7937663 — intervention group
Group type: EXPERIMENTAL
Intervention: multi‐modality therapy using tuberculin, oliphen plus prednisolone
Number of subjects: 82
Study 3348612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (3 g every 12 h) as a single agent
Number of subjects: 14
Study 3348612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam (1.5 g every 12 h) as a single agent
Number of subjects: 14
Study 3348612 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone and sulbactam combination (3/1.5 g)
Number of subjects: 14
Study 29642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 23)
Number of subjects: 47
Study 29642080 — intervention group
Group type: COMPARATOR
Intervention: Propofol (n = 24)
Number of subjects: 47
Study 29642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 47
Study 29642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 47
Study 29642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47
Study 28126455 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention in conjunction with a health risk assessment (HRA)
Number of subjects: 0
Study 28126455 — intervention group
Group type: COMPARATOR
Intervention: Health risk assessment (HRA) alone
Number of subjects: 0
Study 28126455 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 0
Study 25920000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (peak BrAC of 40mg/dL)
Number of subjects: 62
Study 25920000 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose alcohol (peak BrAC of 65mg/dL)
Number of subjects: 62
Study 25920000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (peak BrAC of 0mg/dL)
Number of subjects: 62
Study 24156469 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 40
Study 24156469 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 21977941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 mcg once daily in the evening
Number of subjects: 646
Study 21977941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 mcg twice daily
Number of subjects: 646
Study 21977941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 mcg once daily in the morning
Number of subjects: 646
Study 21977941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study 19179834 — intervention group
Group type: EXPERIMENTAL
Intervention: +F
Number of subjects: 34
Study 19179834 — intervention group
Group type: COMPARATOR
Intervention: ‐F
Number of subjects: 34
Study 16530911 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade clove gel
Number of subjects: 73
Study 16530911 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine 20% gel
Number of subjects: 73
Study 16530911 — intervention group
Group type: COMPARATOR
Intervention: Placebo resembling clove
Number of subjects: 73
Study 16530911 — intervention group
Group type: COMPARATOR
Intervention: Placebo resembling benzocaine
Number of subjects: 73
Study 14603980 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal eye drops (itone eye drops)
Number of subjects: 120
Study 14603980 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear
Number of subjects: 120
Study 14603980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11014949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin antagonist Atosiban (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin)
Number of subjects: 0
Study 11014949 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without primary dysmenorrhea)
Number of subjects: 0
Study 8922872 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 0
Study 8922872 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing IUS
Number of subjects: 0
Study 8922872 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing IUS (postabortal insertion)
Number of subjects: 0
Study 1425870 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (240 mg administered in three divided doses over 22 hours)
Number of subjects: 6
Study 1425870 — intervention group
Group type: COMPARATOR
Intervention: Normochlorhydria (no omeprazole treatment)
Number of subjects: 6
Study 4085165 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field therapy (PEMF)
Number of subjects: 30
Study 4085165 — intervention group
Group type: COMPARATOR
Intervention: Inactive pulsed electromagnetic field therapy (PEMF)
Number of subjects: 30
Study 31293236 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted children's weight management programme (6 sessions)
Number of subjects: 92
Study 31293236 — intervention group
Group type: COMPARATOR
Intervention: Standard (unadapted) children's weight management programme
Number of subjects: 92
Study 30512100 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitor prescription at hospital discharge
Number of subjects: 15896
Study 30512100 — intervention group
Group type: COMPARATOR
Intervention: No RAS inhibitor prescription
Number of subjects: 15896
Study 30512100 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitor prescription at hospital discharge (stratified by preserved LVEF)
Number of subjects: 15896
Study 30512100 — intervention group
Group type: COMPARATOR
Intervention: No RAS inhibitor prescription (stratified by preserved LVEF)
Number of subjects: 15896
Study 30512100 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitor prescription at hospital discharge (KCCQ score analysis)
Number of subjects: 15896
Study 30512100 — intervention group
Group type: COMPARATOR
Intervention: No RAS inhibitor prescription (KCCQ score analysis)
Number of subjects: 15896
Study 26429068 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) meal
Number of subjects: 16
Study 26429068 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HCHO) meal
Number of subjects: 16
Study 25353193 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair tilt and recline at 15, 25, and 35 degrees tilt with 10 and 30 degrees recline
Number of subjects: 13
Study 22267715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero cell culture-derived influenza vaccine
Number of subjects: 100
Study 22267715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19172131 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.3 g x kg(‐1) x day(‐1))
Number of subjects: 102
Study 19172131 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous placebo supplementation - alanine)
Number of subjects: 102
Study 17311977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 0
Study 17311977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb‐12
Number of subjects: 0
Study 15939062 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXO: high ALA, n = 21)
Number of subjects: 57
Study 15939062 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO: high linoleic acid, n = 17)
Number of subjects: 57
Study 15939062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil with fish-oil (SOF n = 19)
Number of subjects: 57
Study 12563465 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding after 24 hours post-operation
Number of subjects: 43
Study 12563465 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeding after ileus resolution
Number of subjects: 43
Study 12563465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 10591888 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg/70 kg)
Number of subjects: 13
Study 10591888 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (300 mg/70 kg; active drug control)
Number of subjects: 13
Study 10591888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7854546 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine administration
Number of subjects: 6
Study 7854546 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 6
Study 1776257 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 81
Study 1776257 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 81
Study 6172922 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar epidural analgesia for up to 24 hours
Number of subjects: 38
Study 6172922 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with intermittent positive pressure ventilation
Number of subjects: 38
Study 25646024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day period of nap restriction (n=13)
Number of subjects: 28
Study 25646024 — intervention group
Group type: COMPARATOR
Intervention: Napping as usual (n=15)
Number of subjects: 28
Study 29219073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tummy time (30 min per day)
Number of subjects: 455
Study 29219073 — intervention group
Group type: EXPERIMENTAL
Intervention: Kept restrained (no more than 1 h at a time)
Number of subjects: 455
Study 29219073 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time (zero screen time)
Number of subjects: 455
Study 29219073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (14-17 h for 0-3 month olds or 12-16 h for 4-11 month olds)
Number of subjects: 455
Study 29219073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined guidelines (meeting all four guidelines)
Number of subjects: 455
Study 29219073 — intervention group
Group type: COMPARATOR
Intervention: Screen time guideline by gender
Number of subjects: 455
Study 29219073 — intervention group
Group type: COMPARATOR
Intervention: Combined guidelines by gender
Number of subjects: 455
Study 25738849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% stabilized retinol
Number of subjects: 62
Study 25738849 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 62
Study 25738849 — intervention group
Group type: EXPERIMENTAL
Intervention: Histochemical markers after retinol treatment
Number of subjects: 62
Study 25738849 — intervention group
Group type: COMPARATOR
Intervention: Histochemical markers after vehicle treatment
Number of subjects: 62
Study 23880355 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose intake
Number of subjects: 3496
Study 23880355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose intake
Number of subjects: 3496
Study 23880355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose intake (nutrient density method)
Number of subjects: 3496